Abstract
The experimental model of infected fibrin clots in rabbits was used to study the penetration and in vivo activity of cefixime against Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus. The respective MICs of cefixime against these strains were 0.25, 2, and 8 micrograms/ml. The clots were infected with 10(6) to 10(8) CFU/g. Groups of four animals for each strain received an intravenous injection of 100 mg of cefixime per kg over 30 min. High peak levels were observed in serum (146.5 micrograms/ml) and clots (15.8 micrograms/g), and the antibiotic was still detectable in the clots (0.6 micrograms/g) 24 h after administration. The respective serum and clot elimination half-lives were 0.7 and 5.0 h. The mean serum protein binding was 23.8 +/- 3.8%. Cefixime was highly bactericidal against K. pneumoniae and E. coli and reduced, over a 24-h period, their respective colony counts by 7.8 log10 and 6.2 log10 CFU/g of fibrin. It was less effective against S. aureus but still reduced the bacterial counts by 2.8 log10 CFU/g of fibrin. The present results demonstrate that cefixime, a new broad-spectrum oral cephalosporin, has a long tissue half-life which ensured, at the dose given here, good in vivo bactericidal activity against both gram-positive and gram-negative bacteria up to 24 h after administration of the antibiotic.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bergeron M. G., Beauchamp D., Poirier A., Bastille A. Continuous vs. intermittent administration of antimicrobial agents: tissue penetration and efficacy in vivo. Rev Infect Dis. 1981 Jan-Feb;3(1):84–97. doi: 10.1093/clinids/3.1.84. [DOI] [PubMed] [Google Scholar]
- Bergeron M. G., Marois Y. Benefit from high intrarenal levels of gentamicin in the treatment of E. coli pyelonephritis. Kidney Int. 1986 Oct;30(4):481–487. doi: 10.1038/ki.1986.211. [DOI] [PubMed] [Google Scholar]
- Bergeron M. G., Nguyen B. M., Trottier S., Gauvreau L. Penetration of cefamandole, cephalothin, and desacetylcephalothin into fibrin clots. Antimicrob Agents Chemother. 1977 Dec;12(6):682–687. doi: 10.1128/aac.12.6.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brittain D. C., Scully B. E., Hirose T., Neu H. C. The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin Pharmacol Ther. 1985 Nov;38(5):590–594. doi: 10.1038/clpt.1985.229. [DOI] [PubMed] [Google Scholar]
- EAGLE H., FLEISCHMAN R., LEVY M. "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. N Engl J Med. 1953 Mar 19;248(12):481–488. doi: 10.1056/NEJM195303192481201. [DOI] [PubMed] [Google Scholar]
- Kurz H., Trunk H., Weitz B. Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. Arzneimittelforschung. 1977 Jul;27(7):1373–1380. [PubMed] [Google Scholar]
- Lavoie G. Y., Bergeron M. G. Influence of four modes of administration on penetration of aztreonam, cefuroxime, and ampicillin into interstitial fluid and fibrin clots and on in vivo efficacy against Haemophilus influenzae. Antimicrob Agents Chemother. 1985 Sep;28(3):404–412. doi: 10.1128/aac.28.3.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Chin N. X., Labthavikul P. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother. 1984 Aug;26(2):174–180. doi: 10.1128/aac.26.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sande M. A., Korzeniowski O. M., Allegro G. M., Brennan R. O., Zak O., Scheld W. M. Intermittent or continuous therapy of experimental meningitis due to Streptococcus pneumoniae in rabbits: preliminary observations on the postantibiotic effect in vivo. Rev Infect Dis. 1981 Jan-Feb;3(1):98–109. doi: 10.1093/clinids/3.1.98. [DOI] [PubMed] [Google Scholar]